CMS subsidiary Dermavon gets China approval for Lumirix atopic dermatitis
CMS says its subsidiary Dermavon has received approval in China for Lumirix for an additional indication of atopic dermatitis.
SHENZHEN, China, Sept. 03, 2026 (Globe Newswire) -- China Medical System Holdings Limited (“CMS” or the “Group”) said its subsidiary, Dermavon Holdings Limited (“Dermavon”), has received approval in China for Lumirix for atopic dermatitis. Dermavon is described as an innovative pharmaceutical company focused on skin health and is applying for a separate listing.